Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05523596 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults
A Phase 1 study of Safety Issues, sponsored by IC-MedTech Corporation.
- Active
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 3
- Study locations
NCT05523596: Active Phase 1 study of Safety Issues, sponsored by IC-MedTech Corporation.
NCT05523596 is a Phase 1 study of Safety Issues that is active but no longer recruiting, run by IC-MedTech Corporation. The registered enrollment target is 13 participants, below the 119-participant average among 13 other Safety Issues trials with a reported enrollment target (89% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05523596, a Phase 1 study of Safety Issues, is active but no longer recruiting, sponsored by IC-MedTech Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Phase 1 Non-Randomized Open Label Study of Oral ICM20
Primary Outcome
Number of participants with treatment related adverse events, based on a modified World Health Organization toxicity grading scale
Conditions Studied
Interventions
- DRUG Benznidazole
- DRUG ICM20
Study Locations (3)
Maryland
- Parkway Medical - Glen Burnie
Texas
- Baylor College of Medicine - Houston
Virginia
- Culmore Clinic - Falls Church
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-12-20 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What the registry record for NCT05523596 still lists
NCT05523596 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 119-participant average among 13 other Safety Issues trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Safety Issues appearing as the primary indexed condition, and to 2 interventions - of which Benznidazole is the first listed.
NCT05523596 reports a single indexed study location in Maryland, Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT05523596 about?
NCT05523596 is a clinical study titled "A Phase 1 Study of the Safety and Tolerability of ICM20 in Adults". A Phase 1 Non-Randomized Open Label Study of Oral ICM20
What is the current status of trial NCT05523596?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2022-12-20. Estimated completion is 2027-03.
What conditions does trial NCT05523596 study?
This clinical trial studies the following conditions: Safety Issues.
What interventions are being tested in trial NCT05523596?
The interventions under investigation include: Benznidazole (DRUG), ICM20 (DRUG).
Who is sponsoring clinical trial NCT05523596?
This trial is sponsored by IC-MedTech Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05523596 being conducted?
This trial has 3 study locations across Maryland, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Safety Issues
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05523596's enrollment target sits among peer trials
13 13th of 13 higher than 1 of 13 other Safety Issues trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Safety Issues trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Role of a CCK Receptor Antagonist Proglumide in Management of Chronic Pancreatitis
ACTIVE NOT RECRUITING · Phase 1
-
A Phase 1 Study of EXT608 in Healthy Adults
COMPLETED · Phase 1
-
Rectal Insert TAF/EVG Pre-Exposure Prophylaxis (RITE PrEP) Study
COMPLETED · Phase 1
-
Oral Remimazolam With and Without Alcohol in Healthy Female Subjects
COMPLETED · Phase 1
-
Pupillary Unrest in Ambient Light, and Relationship to Opioid-Induced Respiratory Depression
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI